A hospice-first, evidence-based clinical reference for clinicians, families, and patients navigating this diagnosis at end of life. Built for the team beside the bed.
Duchenne muscular dystrophy — the disease, the biology, the survival transformation, and what the hospice team must understand on day one when caring for a young adult who has lived inside this diagnosis his entire life.
Duchenne muscular dystrophy is the most common severe neuromuscular disease of childhood, caused by loss-of-function mutations in the DMD gene that eliminate functional dystrophin — the structural protein that anchors the intracellular actin cytoskeleton of muscle cells to the extracellular matrix through the dystrophin-associated protein complex (DAPC). Without functional dystrophin, the sarcolemma is mechanically fragile during muscle contraction, producing cycles of calcium influx, myofiber necrosis, inflammation, and inadequate regeneration. Over years, skeletal muscle is progressively replaced by fibrofatty tissue, generating the characteristic proximal weakness, pseudohypertrophy of the calves, and sequential loss of motor function that defines the DMD clinical course.[1] The same pathological process affects cardiac muscle, producing the dilated cardiomyopathy of dystrophinopathy that becomes the second leading cause of death as respiratory management extends overall survival, and smooth muscle, producing the gastrointestinal dysmotility that complicates end-stage nutritional management.[3]
The DMD disease course follows a predictable sequential decline that has been carefully characterized across decades of natural history data: ambulation is typically lost between ages 9–12 (earlier without corticosteroids, later with deflazacort or prednisone); scoliosis progresses rapidly following loss of ambulation when the stabilizing effect of axial loading is removed; forced vital capacity (FVC) begins its irreversible decline, crossing the 50% predicted threshold that triggers initiation of nocturnal non-invasive ventilation (NIV), then progressing to continuous 24-hour NIV dependence as respiratory muscles weaken further; dilated cardiomyopathy emerges and requires ACE inhibitor and beta-blocker management; and the patient arrives at the hospice encounter as a young adult — typically in his mid-to-late 20s or early 30s — cognitively intact, carrying 20 years of lived expertise in his own disease, fully capable of autonomous medical decision-making, and entitled to have every clinical decision anchored to his preferences.[2][4]
The survival transformation in DMD — from a median survival of approximately 19 years in the pre-corticosteroid, pre-NIV era to 25–30 years today, with survival into the 40s achievable with tracheostomy ventilation — has transformed DMD from a pediatric disease into a young adult disease. The hospice clinical framework must therefore address the specific and non-negotiable needs of young adults dying from a disease they have known since early childhood: the autonomy of a cognitively intact adult; the continuity disruption of the pediatric-to-adult medical transition; the disease-specific expertise the patient brings to every clinical encounter; and the particular existential weight of a person who has watched his own body fail in a predetermined sequence across his entire life.[5]
The young man with Duchenne who arrives at hospice has been living inside this disease since he was approximately five years old. He watched the disease take his ability to walk, then his ability to raise his arms above his shoulders, then his ability to breathe without a machine. He has been cared for — ideally — by a comprehensive pediatric neuromuscular team that he and his family knew for fifteen years. He has read the clinical literature. He has participated in DMD patient advocacy communities. He can explain the dystrophin-associated protein complex, tell you his mutation type and the exons affected, recite his FVC trajectory over the last five years, and describe his NIV settings without looking them up. The hospice clinician who walks into a DMD home must come prepared to learn from the patient first. Ask what has been working in his care and what has not. Ask what matters most to him. Ask what he knows about his disease course and where he thinks he is in it. The clinical assessment follows the conversation — not the other way around.
DMD diagnosis is established long before hospice enrollment. This section equips the hospice clinician to read the prior records, reconstruct the clinical history, and perform the respiratory, cardiac, and functional inventory that must be completed at enrollment to prevent avoidable crises.
Respiratory assessment — the most urgent inventory at enrollment:
Your person's diagnosis of Duchenne muscular dystrophy was made years — probably decades — ago. The hospice team is not here to re-diagnose or re-stage the disease. We are here to review the most recent records about his breathing machine, his heart, and his other medical needs so that we can provide the best possible care. If you have copies of recent lung function tests (spirometry), echocardiograms (heart ultrasounds), or clinic notes from his neuromuscular team, please share them with the hospice nurse at the first visit — they are invaluable for understanding where things stand and what to prepare for.
El diagnóstico de su persona ya está establecido. El equipo de hospicio está aquí para revisar los registros médicos recientes y brindar el mejor cuidado posible. Próximamente en español.
Dystrophin absence and its multi-system consequences — the pathophysiology that explains ventilatory failure, cardiomyopathy, GI dysmotility, and cognitive involvement. Understanding the mechanism is essential to anticipating and managing every complication at end of life.
The diaphragm and intercostal muscles are skeletal muscle and are subject to the same dystrophinopathy-driven necrosis as limb muscles. Progressive respiratory muscle weakness reduces tidal volume, increases the dead space fraction of each breath, and eventually produces hypercapnic respiratory failure. The sequence is predictable:[8]
Dilated cardiomyopathy of dystrophinopathy: Dystrophin is expressed in cardiac muscle in the same structural role as in skeletal muscle. Its absence produces progressive fibrofatty replacement of cardiomyocytes, initially in the posterolateral left ventricle (detectable on cardiac MRI as late gadolinium enhancement before LVEF decline), progressing to diffuse left ventricular dilation, systolic dysfunction, and dilated cardiomyopathy. Unlike most dilated cardiomyopathies, DMD cardiomyopathy responds well to ACE inhibitors and beta-blockers — multiple trials show that early initiation of perindopril delays the onset of LV dysfunction and improves survival.[10][13] These medications must not be discontinued at hospice enrollment.
Duchenne muscular dystrophy is caused by a change in a single gene — the DMD gene — that prevents the body from making the dystrophin protein that keeps muscle cells strong. This gene change is present from birth. It is not caused by anything your person ate, was exposed to, or did. It is not caused by anything you did during pregnancy. In about one-third of cases, the gene change is new — it was not inherited from either parent, and no one in the family had it before. In two-thirds of cases, the gene change is inherited through the mother (who is typically a carrier with no symptoms). Your family did not cause this. Nothing you could have done would have prevented it. The question now is how we take the best possible care of your person with the understanding we have today.
Even at hospice enrollment, a referral for genetic counseling for the patient's family is appropriate and potentially life-saving. DMD is X-linked recessive: the patient's mother has a 50–67% probability of being a carrier. A carrier mother has a 50% chance of having an affected son and a 50% chance of having a carrier daughter with each pregnancy. Female carriers are at increased risk of dilated cardiomyopathy themselves — this risk is under-recognized and underscreened. The patient's sisters may be carriers and should be offered testing. The hospice social worker can facilitate a warm handoff to a genetics team for carrier testing and family counseling, independent of the patient's own care trajectory. This is one of the most important public health actions the hospice team can take in a DMD enrollment, and it should not be deferred because the patient is near end of life.[17]
DMD end-stage management: NIV optimization and the withdrawal decision, cardiomyopathy management that must not be deprescribed, corticosteroid safety, CoughAssist protocol, scoliosis pain management, PEG decisions in a cognitively intact patient, and disease-modifying therapies at hospice stage.
DMD end-stage treatment management is defined by four non-negotiable safety priorities that must be established at the first hospice visit, before any other clinical assessment proceeds. First: verify that NIV settings are therapeutically optimized, that the mask interface is comfortable and not causing pressure injury, and that the CoughAssist device is present, operational, and that the family is trained on its use — these are the respiratory safety foundation that prevents the secretion crises and NIV failure that drive the most common DMD hospice emergencies.[8] Second: confirm that the ACE inhibitor and beta-blocker are present in the medication list and document the never-stop instruction prominently — these medications are actively preventing cardiac decompensation in a dilated cardiomyopathy and are not candidates for deprescribing at hospice enrollment.[10] Third: calculate the minimum physiological corticosteroid replacement dose and document the adrenal insufficiency risk — the patient who has been on deflazacort since age 5 or 6 has complete hypothalamic-pituitary-adrenal (HPA) axis suppression and cannot withstand corticosteroid cessation without risk of adrenal crisis.[11] Fourth: pre-position the NIV withdrawal comfort medications — opioids and anxiolytics drawn, labeled, and accessible — before any NIV withdrawal conversation concludes, because the withdrawal of NIV from a fully ventilator-dependent patient is functionally equivalent to ventilator withdrawal in the ICU, and comfort medications must be available before the moment of withdrawal.[12]
Beyond these four acts, DMD end-stage management addresses scoliosis-related positional pain, PEG decisions and site management, and the status of disease-modifying exon-skipping therapies — each requiring the careful clinical framework described below.
NIV in DMD is simultaneously a life-sustaining treatment, a comfort measure, and — at end stage — the focus of the most consequential clinical decision in DMD hospice: the decision about whether and when to withdraw ventilatory support. The hospice team's NIV management responsibilities at enrollment include:[8]
DMD cardiomyopathy — never deprescribe ACE-I and beta-blocker: The ACE inhibitor (lisinopril or perindopril) and beta-blocker (carvedilol or metoprolol succinate) are the cornerstones of DMD cardiomyopathy management and must not be discontinued at hospice enrollment. The Duboc PERION trial demonstrated that perindopril initiated before LV dysfunction delays the onset of cardiomyopathy; subsequent data confirm that ACE inhibitor and beta-blocker continuation provides symptomatic benefit and prevents acute decompensation in established DMD dilated cardiomyopathy. The covering clinician who sees LVEF 28% and "simplifies" the medication list by stopping carvedilol and lisinopril has caused a rapid cardiac deterioration that is both preventable and potentially irreversible. Document "ACE INHIBITOR AND BETA-BLOCKER: NEVER DISCONTINUE IN DMD CARDIOMYOPATHY" in the medication safety section with the same prominence as an allergy.[10][13] Continue diuretics (furosemide) for fluid overload symptoms; monitor potassium closely with concurrent ACE-I and spironolactone; avoid over-diuresis (narrow therapeutic window in volume-sensitive dilated cardiomyopathy).
Corticosteroid management — minimum physiological dose forever: The patient who has been on deflazacort or prednisone since early childhood has complete HPA axis suppression and cannot mount an endogenous cortisol response to physiological stress. Deflazacort 0.3 mg/kg/day equivalent (or prednisone 0.1 mg/kg/day as minimum physiological replacement) must be maintained indefinitely. The 2 AM covering clinician who stops the deflazacort while simplifying medications has caused a potentially fatal adrenal crisis. Document the minimum dose explicitly with the adrenal insufficiency warning.[11]
CoughAssist (mechanical in-exsufflation) for secretion clearance: The CoughAssist device applies a positive pressure breath (+40 cmH₂O insufflation) followed by rapid switch to negative pressure (−40 cmH₂O exsufflation) to simulate a cough in a patient whose expiratory muscle weakness has reduced peak cough flow below the threshold for effective airway clearance. Standard protocol: 5 cycles per treatment, 3–5 treatments per session, 2–4 sessions per day during active illness, 1–2 sessions per day for maintenance. At enrollment: verify the device is operational; verify family training; document the current pressure settings; prescribe preventive treatment protocol during any respiratory illness. This device is the single most important intervention for preventing the retained secretion pneumonias that drive DMD hospice crises.[9]
Scoliosis pain management: DMD scoliosis — which progresses rapidly after loss of ambulation — both restricts chest wall expansion (worsening respiratory reserve) and produces positional pain from asymmetric loading of the scoliotic curve, pressure injury from scoliotic seated positioning, and hip and low back pain from the postural deformity. Pain management requires: NSAIDs or acetaminophen for inflammatory-positional pain (titrated against renal function and GI tolerance); low-dose opioids for refractory positional pain; seating specialist referral for custom wheelchair seating to reduce asymmetric pressure loading; repositioning schedule with written protocol for family caregivers.[18]
PEG decisions in a cognitively intact patient: DMD-related dysphagia from bulbar and pharyngeal muscle weakness, combined with GI dysmotility from smooth muscle dystrophinopathy, creates a nutritional management challenge that is philosophically distinct from PEG decisions in advanced dementia (Card #41). The DMD patient with intact cognition can express preferences about PEG — and those preferences must be honored. Some patients choose PEG for nutritional optimization and medication delivery; others decline PEG and prefer oral feeding with aspiration risk accepted as a quality-of-life trade-off. The oral comfort feeding framework — honoring the patient's preference for oral intake even at aspiration risk — applies fully here. If a PEG is in place: assess the site at every nursing visit; manage gastric emptying dysfunction with prokinetics; document gastric residual protocol with the family.[15]
Disease-modifying therapies at hospice stage: Exon-skipping therapies (eteplirsen for exon-51-amenable mutations, golodirsen for exon-53, casimersen for exon-45) provide modest functional benefit in ambulatory or recently non-ambulatory DMD patients. At end stage — continuous NIV dependence, LVEF below 30%, complete functional dependence — the benefit-to-burden ratio of continuing infusion-based exon-skipping therapy is low and the patient's own preference should anchor the decision. Do not discontinue unilaterally; discuss with the patient and the prescribing neuromuscular team. Gene therapies (e.g., delandistrogene moxeparvovec) are in clinical development; at hospice stage they are not standard of care. Corticosteroids (deflazacort or prednisone) remain the highest-evidence disease-modifying intervention in DMD and must be continued at minimum physiological replacement dose as described above.[6][11]
Evidence-based criteria for continuing and initiating disease-directed therapies in DMD at end of life. In Duchenne, many of the most critical interventions — NIV, cardiac medications, CoughAssist, corticosteroids — are simultaneously comfort measures and life-sustaining treatments. Knowing when each still serves the patient is the core clinical skill.
In DMD hospice, "when therapy makes sense" is not a question about curative intent. It is a question about which ongoing interventions reduce suffering, prevent preventable crises, and honor the patient's goals — and which have crossed into burden without benefit. The Birnkrant 2018 DMD care consensus is explicit: respiratory and cardiac management do not stop at hospice enrollment; they are restructured around comfort.[2] The NIV settings check, the CoughAssist protocol, the ACE inhibitor and beta-blocker, the minimum corticosteroid dose, and the advance directive for NIV withdrawal are not optional clinical tasks — they are the enrollment checklist that prevents the most common and most preventable DMD hospice crises.
The interventions, practices, and prescribing patterns that cause harm in DMD at end of life. Some of the most dangerous clinical errors in DMD hospice are acts of omission — the cardiac medication that was stopped, the corticosteroid that was tapered, the NIV withdrawal that happened without the patient's documented consent.
In DMD hospice, clinical harm most commonly arrives not from overtreatment but from the discontinuation of medications and interventions that were actively preventing decompensation. The covering clinician who sees a complex medication list and applies standard hospice deprescribing logic — reducing medications that are not producing immediate symptomatic benefit — can precipitate rapid cardiac failure by stopping carvedilol, adrenal crisis by stopping deflazacort, and hypercapnic respiratory failure by reducing NIV hours without the patient's consent. The items below are the specific clinical actions that must not occur.[2]
Standard hospice deprescribing frameworks — reducing medications that are not producing immediate symptomatic relief — are dangerous when applied without DMD-specific clinical knowledge. In DMD, the carvedilol, lisinopril, and deflazacort that appear on a complex medication list are not medications that can be safely removed. They are the pharmacological scaffolding that is maintaining cardiac compensation and adrenal function. Before any medication reduction in DMD hospice, the hospice medical director should personally review which medications fall into this category and document explicitly that they are non-negotiable. The covering on-call clinician must be informed at every handoff.
Evidence-graded integrative, device-based, and complementary approaches for DMD at end of life. Grade A = RCT or clinical guideline-endorsed; B = multi-observational, meta-analysis, or strong case-series; C = limited clinical, notable preclinical, or expert consensus; D = case report or emerging without clinical data.
Evidence grading, dosing where supported, and specific interaction flags for DMD. The corticosteroid-supplement interaction, cardiac medication interactions, PEG route compatibility, and the limited-but-real evidence for mitochondrial support supplements require individualized assessment. The patient has likely researched every one of these supplements himself.
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit in DMD | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Coenzyme Q10 (Ubiquinol) | Grade C | 100–300 mg daily with fat-containing meal; ubiquinol form preferred over ubiquinone for bioavailability | Secondary mitochondrial dysfunction from calcium-mediated mitochondrial damage in DMD cycles of myofiber necrosis has generated interest in CoQ10; small RCTs in DMD have not shown consistent functional improvement but suggest reduction in oxidative stress markers; primary benefit rationale is mitochondrial membrane support during ongoing myonecrosis[45] | Mild CYP3A4 interaction — may modestly reduce deflazacort exposure; monitor for subtle corticosteroid under-dosing. May have mild additive hypotensive effect with ACE inhibitor and diuretic — monitor blood pressure. PEG compatibility: ubiquinol softgels can be opened and mixed with fat-containing formula. Generally well tolerated; GI upset at doses above 300 mg/day |
| Vitamin D3 (Cholecalciferol) | Grade B | 2,000–4,000 IU daily; target serum 25-OH vitamin D 40–60 ng/mL; higher doses (50,000 IU weekly) if deficient at enrollment | Deflazacort and corticosteroids markedly impair intestinal calcium absorption and accelerate bone turnover — DMD patients on lifetime steroids have significant osteoporosis by young adulthood; vitamin D3 with calcium supplementation is guideline-supported for steroid-induced osteoporosis prevention; vitamin D deficiency (common in wheelchair-dependent individuals with limited sun exposure) also impairs muscle function and immune response[19] | Hypercalcemia risk if dosed aggressively in combination with calcium supplements — check serum calcium at 3 months when starting high-dose vitamin D. Minimal CYP interaction. PEG compatible: vitamin D3 drops are available in liquid formulation. Rare hypersensitivity in granulomatous disease — not typically relevant in DMD. Safe at target doses in cardiac patients |
| Omega-3 Fatty Acids (EPA/DHA Fish Oil) | Grade C | 2–4 g EPA+DHA daily in divided doses with meals; enteric-coated formulations reduce GI intolerance; liquid formulation available for PEG | Anti-inflammatory effects from omega-3 fatty acids have preclinical plausibility in DMD — the ongoing cycle of myofiber necrosis and inflammatory infiltration in dystrophic muscle is modulated by the omega-3/omega-6 balance; mouse model studies (mdx mouse) show membrane stabilization with omega-3 supplementation; human DMD trial data are limited to small observational studies showing reduced inflammatory markers[46] | Mild antiplatelet effect — relevant if patient is on aspirin or anticoagulation; no significant interaction with ACE inhibitors or beta-blockers at standard doses. Mild hypotensive effect — monitor if combined with diuretics and ACE inhibitor. May lower triglycerides — beneficial in steroid-exposed patients. PEG compatible in liquid form. Fishy breath and GI upset common — enteric coating mitigates. Monitor LFTs if doses above 4 g/day long-term |
| Creatine Monohydrate | Grade C | 3–5 g daily (maintenance dose); no loading phase needed; mix in fluid or enteral formula; PEG compatible as powder dissolved in water | Creatine supplementation in DMD has been studied in multiple small RCTs with mixed results — some trials show modest improvement in grip strength and functional scores; no trial shows benefit in end-stage DMD; the theoretical rationale (augmenting creatine phosphate energy buffering in dystrophin-deficient muscle) is plausible but the muscle at end stage has extensive fibrofatty replacement and limited residual fiber mass to benefit from energy substrate supplementation[47] | Renal handling: creatine supplementation raises serum creatinine through non-pathological mechanisms (creatinine is the catabolite of creatine phosphate); this may confound renal function monitoring in a patient on ACE inhibitor — note baseline creatinine trend before starting. Generally safe at 5 g/day in patients without pre-existing renal disease. No significant cardiac medication interaction. PEG compatible as dissolved powder. GI bloating common; divide dose or reduce if symptomatic |
| Green Tea Extract (EGCG — Epigallocatechin Gallate) | Grade D | 400–800 mg EGCG daily (standardized extract); green tea beverage is an alternative for patients without PEG; avoid on empty stomach | EGCG has preclinical evidence in mdx mouse models showing reduction of utrophin upregulation-independent muscle protection, anti-inflammatory effects, and reduction of oxidative stress markers in dystrophin-deficient muscle; human DMD trial data are absent; interest from DMD research community is based on the multi-target antioxidant mechanism that addresses several of the secondary pathogenic pathways in dystrophinopathy[48] | Significant CYP3A4 inhibition: EGCG meaningfully inhibits CYP3A4 and can increase deflazacort plasma levels by 30–50% — this is the most important interaction in the DMD supplement profile; if EGCG is used alongside deflazacort, monitor for corticosteroid toxicity (hyperglycemia, fluid retention, mood changes) and consider deflazacort dose reduction. Also inhibits OATP1B1 (similar to grapefruit) — monitor for statin interactions if applicable. Hepatotoxicity risk at high doses (above 800 mg EGCG/day) — avoid in patients with elevated LFTs. PEG: soluble in warm water |
| Curcumin (Turmeric Extract) | Grade D | 500–1,000 mg curcumin with piperine (black pepper extract, 5–20 mg) for bioavailability; or phospholipid-complexed formulation (Meriva, Phytosome); 2–3 times daily with food | Curcumin modulates NF-κB inflammatory signaling — the same pathway activated by the repeated myofiber necrosis-inflammation cycles of DMD; mdx mouse studies show reduced inflammatory infiltrate and improved muscle histology; human data in DMD are absent; curcumin is discussed extensively in the DMD patient community based on the preclinical plausibility, making it one of the most common supplements patients report using[49] | CYP3A4 inhibitor: Curcumin inhibits CYP3A4 and may increase deflazacort plasma levels; same monitoring precautions as EGCG apply. Mild antiplatelet effect — relevant if on NSAIDs or aspirin. May decrease iron absorption if taken with iron supplements. GI intolerance common — the piperine and fat required for absorption contribute to GI symptoms in gastroparesis-prone DMD patients; start at low dose. PEG compatible in capsule-opened powder form mixed with formula |
| Melatonin | Grade C | 0.5–3 mg at bedtime (lowest effective dose); avoid doses above 5 mg — higher doses do not improve efficacy and increase morning sedation; immediate-release formulation for sleep initiation; sustained-release for sleep maintenance problems | Sleep fragmentation is a significant comfort burden in DMD — NIV mask discomfort, nocturnal hypoventilation awakening, positional pain, and anxiety all contribute to disrupted sleep; melatonin at low doses has evidence for sleep initiation improvement without the respiratory depressant effects of benzodiazepines; in patients with nocturnal hypoxemia, improving sleep architecture may improve daytime cognition and comfort perception[52] | Mild CYP1A2 inhibitor — low interaction significance with DMD medication list. May have mild hypotensive effect — not clinically significant at standard doses. Avoid doses above 5 mg in patients with depression (paradoxical worsening of mood at high melatonin doses has been reported). PEG compatible: liquid formulations available. No interaction with carvedilol, lisinopril, or deflazacort at standard doses. Avoid combination with sedating antihistamines or opioids at bedtime — additive sedation risk in the patient who requires NIV compliance overnight |
| Magnesium (Glycinate or Malate) | Grade C | 200–400 mg elemental magnesium daily in divided doses; glycinate and malate forms preferred for GI tolerability; malate form may have additional mitochondrial benefit (malic acid is a TCA cycle intermediate) | Magnesium deficiency is common in patients on chronic diuretics (furosemide causes renal magnesium wasting) and chronic corticosteroids (deflazacort increases renal magnesium excretion); deficiency contributes to muscle cramps and spasticity, cardiac arrhythmia susceptibility, fatigue, and anxiety; in DMD the deflazacort-furosemide combination makes hypomagnesemia clinically likely and underdiagnosed; serum magnesium below 1.8 mg/dL warrants supplementation regardless of symptoms[53] | Monitor serum magnesium in conjunction with BMP — BMP does not include magnesium; order separately. Hypermagnesemia risk if renal function declines on ACE inhibitor therapy — hold supplemental magnesium if creatinine doubles above baseline. Magnesium oxide forms cause GI diarrhea — avoid in DMD gastroparesis patients; use glycinate or malate. PEG compatible as powder dissolved in water. Mild additive hypotensive effect with ACE inhibitor at high doses — use standard supplemental doses only |
A guide, not a prediction. The DMD timeline spans an entire childhood and young adulthood — from diagnosis in early childhood to death in the late 20s or 30s. This is the longest timeline in this card series. Every phase is shaped by corticosteroid use, NIV initiation timing, cardiac management, and the individual patient's choices about invasive ventilation.
Duchenne muscular dystrophy follows a more predictable sequential decline than almost any other disease in medicine — the natural history has been characterized in meticulous detail over decades of neuromuscular registry data.[1] In the pre-corticosteroid, pre-NIV era, median survival was approximately 19 years; with systematic corticosteroid use and non-invasive ventilation, median survival has extended to 25–30 years and continues to improve.[2] The hospice clinician who works with DMD must understand the entire arc — not just the final months — because the patient has lived every phase of this disease and carries that history into every clinical encounter. The most important clinical timeline fact in DMD hospice: the transition from pediatric to adult care that occurs at age 18 is a period of extreme clinical vulnerability — many complications and hospitalizations cluster in the first two years after transition.[3]
DMD medication management at hospice is dominated by three non-negotiable safety priorities that must be addressed before any other clinical action. Beyond those: NIV-directed comfort pharmacology, cardiac management, secretion control, scoliosis pain, and GI symptom management.
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Lisinopril or Perindopril |
ACE Inhibitor / DMD Dilated Cardiomyopathy | Lisinopril 5–20 mg PO daily Perindopril 2–8 mg PO daily |
⚠ NEVER DISCONTINUE AT HOSPICE ENROLLMENT — DMD cardiomyopathy. These drugs are actively preventing cardiac remodeling progression and acute decompensation. The PERION trial demonstrated mortality benefit with perindopril in DMD cardiomyopathy.[11] Monitor potassium monthly if concurrent spironolactone. Adjust dose for renal impairment — but do not stop. Document indication prominently. Document: "ACE INHIBITOR — NEVER DISCONTINUE IN DMD CARDIOMYOPATHY" in medication safety section. |
| Carvedilol or Metoprolol succinate |
Beta-Blocker / DMD Dilated Cardiomyopathy | Carvedilol 3.125–25 mg PO BID Metoprolol succinate 12.5–100 mg PO daily |
⚠ NEVER DISCONTINUE AT HOSPICE ENROLLMENT — DMD cardiomyopathy. Beta-blocker for cardiac remodeling, arrhythmia suppression, and symptom management. Do not stop for "hospice simplification." Do not reduce dose without cardiology guidance. Carvedilol preferred in DMD for combined alpha/beta blockade benefit in dilated cardiomyopathy.[12] Document: "BETA-BLOCKER — NEVER DISCONTINUE IN DMD CARDIOMYOPATHY" in medication safety section. |
| Deflazacort or Prednisone |
Corticosteroid / Disease Modification + Adrenal Replacement | Deflazacort: minimum 6 mg PO daily Prednisone: minimum 5 mg PO daily (minimum physiological replacement) |
⚠ NEVER STOP — LIFETIME HPA AXIS SUPPRESSION — ADRENAL INSUFFICIENCY RISK. The patient who has been on deflazacort since age 6 has a completely suppressed hypothalamic-pituitary-adrenal axis. The minimum physiological replacement dose must be maintained even if disease-modifying benefit is no longer the goal. During physiological stress (infection, surgery, crisis), dose must be increased (stress dosing: 2–3× baseline). Calculate and document the minimum dose at enrollment.[4] Adrenal crisis symptoms: hypotension, nausea, vomiting, abdominal pain, confusion, hemodynamic collapse. Have stress-dose hydrocortisone injection available. |
| Furosemide | Loop Diuretic / Fluid Overload — Cardiac Decompensation | 20–80 mg PO/IV/SQ daily or BID | For symptomatic fluid overload and dyspnea from left ventricular failure. ⚠ Titrate conservatively. DMD patients have a narrow therapeutic window — the preload-dependent dilated cardiomyopathy can be destabilized by aggressive diuresis; over-diuresis reduces cardiac output and worsens overall hemodynamics. Target: symptom relief of dyspnea and edema, not "dry" weight. Monitor weight trend daily if feasible. Monthly BMP for potassium. Monitor potassium closely with concurrent ACE inhibitor and spironolactone. Potassium supplementation may be needed if aggressive diuresis required. |
| Spironolactone | Aldosterone Antagonist / Cardiac Remodeling + Diuresis | 25–50 mg PO daily | Adjunctive cardiac medication in DMD dilated cardiomyopathy — aldosterone antagonism reduces cardiac fibrosis progression. ⚠ Hyperkalemia risk with concurrent ACE inhibitor. Monthly potassium monitoring. Do not discontinue without cardiology guidance. Concurrent use with ACE inhibitor and furosemide is common in advanced DMD heart failure.[12] |
| Morphine | Opioid / Dyspnea + Air Hunger | 2.5–5 mg PO/SQ q4h ATC + 2.5–5 mg SQ PRN q1h For NIV withdrawal: 5–10 mg SQ immediately |
First-line for dyspnea and air hunger in DMD ventilatory failure. Systemic opioids reduce the subjective sensation of air hunger — they do not hasten death when used for comfort-directed dyspnea management. The dose for acute NIV withdrawal is higher than routine dyspnea management and must be administered before NIV removal, not after. Pre-draw and label at enrollment. Titrate based on patient-reported dyspnea, not respiratory rate or oxygen saturation.[13] Route: oral route preferred if PEG is in place and patient is not in acute distress; SQ for acute NIV withdrawal and moderate-severe distress. IV access is rarely established in DMD home hospice. |
| Midazolam | Benzodiazepine / NIV Withdrawal Anxiety + Terminal Distress | 2.5–5 mg SQ PRN q1h For NIV withdrawal: 2.5–5 mg SQ immediately pre-removal |
⚠ Must be pre-positioned at enrollment for NIV withdrawal. Midazolam addresses the anxiety and air hunger component of NIV withdrawal — the sensation of suffocation that the patient who is NIV-dependent will experience without adequate anxiolytic pre-treatment. Administer before NIV is removed, not as rescue after distress appears. Works synergistically with morphine for the dyspnea-anxiety complex. Pre-draw, label, and make accessible at the bedside before NIV withdrawal discussion concludes.[10] Family training in SQ injection technique is critical — the clinician cannot always be present for an unanticipated NIV withdrawal crisis. |
| Lorazepam | Benzodiazepine / Anxiety + Anticipatory Distress | 0.5–1 mg PO/SL q6h PRN or SQ q6h PRN |
For the anxiety component of dyspnea and for anticipatory anxiety around ventilator dependence. Longer acting than midazolam — useful for scheduled anxiety management rather than acute NIV withdrawal crisis. Sublingual route is practical when oral swallowing is compromised. Available in oral concentrate (2 mg/mL) compatible with PEG administration. Can be given SL from the injectable formulation if oral formulation unavailable. |
| Gabapentin | Anticonvulsant / Neuropathic Pain + Scoliosis Pain | 100–300 mg PO TID (titrate to effect; max 3600 mg/day) |
For neuropathic and musculoskeletal pain from scoliosis, contractures, and the positional discomfort of advanced DMD. Evidence for neuropathic pain; clinical evidence for scoliosis-related pain is extrapolated from the neuropathic pain framework. Sedation is the dose-limiting side effect — monitor in the context of concurrent NIV use and respiratory depression risk. Available as liquid suspension for PEG administration. Dose reduction required with any renal impairment.[14] |
| Baclofen | Muscle Relaxant / Spasticity + Positional Pain | 5–20 mg PO TID (or per existing intrathecal pump schedule) |
For spasticity and the musculoskeletal component of positional discomfort in end-stage DMD. ⚠ Never abrupt discontinuation — baclofen withdrawal produces seizures and severe autonomic instability. If the patient has an intrathecal baclofen pump, document pump settings, last refill date, and battery status at enrollment. Available as oral solution for PEG administration. Sedation additive with opioids and benzodiazepines. |
| Glycopyrrolate | Anticholinergic / Secretion Management | 0.2 mg SQ q4h PRN or 0.6–1.2 mg/24h SQ infusion |
Reduces airway and oral secretions that accumulate when cough effectiveness is lost. Preferred over hyoscine (scopolamine) in cognitively intact patients — glycopyrrolate does not cross the blood-brain barrier and produces no CNS effects (delirium, sedation). Used in conjunction with CoughAssist for secretion management, not as replacement for mechanical cough assistance. Also available as oral solution for PEG administration (1 mg/5 mL).[9] |
| Omeprazole or Pantoprazole |
Proton Pump Inhibitor / GI Protection | Omeprazole 20–40 mg PO/PEG daily Pantoprazole 40 mg PO/IV/PEG daily |
GI mucosal protection for the long-term corticosteroid use that persists into hospice. DMD patients have been on chronic corticosteroids for 15–25 years — GI protection is a standard component of the medication regimen. Omeprazole oral solution is available and compatible with PEG administration. Pantoprazole IV is available if PEG access is compromised. Note: omeprazole oral suspension must be stored at room temperature; mixing instructions must be followed for PEG patency. |
| Metoclopramide | Prokinetic / Gastroparesis + Nausea | 5–10 mg PO/PEG q6h AC | For the gastroparesis that is part of the smooth muscle dystrophinopathy in DMD — autonomic involvement produces delayed gastric emptying that compounds the discomfort of tube feeding, causes nausea, and contributes to the reflux that threatens the respiratory status of ventilator-dependent patients.[15] ⚠ Limit to ≤12 weeks to reduce tardive dyskinesia risk. If longer-term prokinetic effect needed, consider domperidone where available or erythromycin 125–250 mg AC as alternative. Do not use in complete bowel obstruction. |
| Docusate + Sennosides | Stool Softener + Stimulant Laxative / Constipation | Docusate 100 mg PO/PEG BID Sennosides 8.6–17.2 mg PO/PEG BID |
Constipation is universal in end-stage DMD — smooth muscle GI dysmotility plus opioid use plus immobility. A scheduled bowel regimen is mandatory from day one. Available in liquid formulations compatible with PEG. If constipation is not managed, the discomfort and distension significantly worsen dyspnea (elevated diaphragm), nausea, and anxiety. Target: one bowel movement every 2–3 days at minimum. Escalate to PEG-compatible polyethylene glycol (MiraLax) if stimulant laxative inadequate. |
| Melatonin | Sleep Aid / Sleep-Disordered Breathing + Insomnia | 0.5–10 mg PO/PEG at bedtime | For sleep onset and maintenance difficulties in DMD — related to nocturnal hypoventilation, NIV discomfort, anxiety, and the physiological sleep disruption of progressive respiratory failure. Preferred over benzodiazepines for chronic sleep management because it lacks respiratory depressant effects that could compromise ventilation. Start low (0.5–1 mg) and titrate up. Extended-release formulations are available. Compatible with PEG administration if crushed (immediate release only — do not crush extended release). |
Twelve clinical pearls specific to Duchenne muscular dystrophy at end of life — from the cognitively intact patient who knows more about his disease than most clinicians, to the NIV withdrawal that must be prepared for before it is needed, to the pediatric-to-adult transition that is one of the most dangerous medical handoffs in medicine.
The existential weight of a lifetime diagnosis, the DMD community as peer support, the parent who has been caregiving since age five, sexuality and intimacy in young adults, legacy work for a 26-year-old, and the advance directive conversation with a cognitively intact young man who knows exactly what is coming.
The young man with Duchenne muscular dystrophy who arrives at hospice at age 26 did not receive a terminal diagnosis at 50 from a disease he had not anticipated. He has known his diagnosis since he was five years old. He grew up inside the knowledge of what was coming — the loss of walking, the loss of hand function, the respiratory decline, the ventilator, the shortened life. He has lived every stage of this disease with the foreknowledge that the next stage was arriving, and he has had twenty years to build — and to exhaust — his psychological resources for meeting it.[52] The hospice clinician who treats the psychosocial assessment of a DMD patient as routine has missed the most specific thing about this disease: there is no moment of diagnosis shock at end of life. The existential crisis in DMD is different — it is the crisis of watching the sequential arrival of losses you have always known were coming, one by one, for two decades, and finding the reserves to keep going.
Your job is not to provide the answers. Your job is to ask the questions that have never been asked with the depth they deserve — and to create the space in which a cognitively intact young adult who has been managing this disease since childhood can finally be heard in a way that clinical medicine has rarely made room for.
Depression prevalence in DMD is 20–30% — substantially higher than in age-matched peers without a chronic illness, and concentrated in the adolescent and young adult years when functional losses accelerate.[52] At end stage, distinguish carefully:
The specific existential burden of DMD is the burden of sequential watching — the patient has watched every stage of loss arrive, has anticipated the next stage, and is now watching end-stage with full cognitive awareness and no cognitive escape.[52]
The young man with DMD has almost certainly built his closest peer relationships through the DMD community — through the Parent Project Muscular Dystrophy (PPMD), the Muscular Dystrophy Association (MDA), and disease-specific social media groups where other young men with Duchenne understand the disease from the inside in a way that no clinician, family member, or friend without DMD can replicate.[53] These connections may have been maintained entirely online — many DMD patients cannot travel to meet their community in person. At enrollment, ask: "Who are the people you feel most connected to about your disease?" The answer will often name people the patient has never met in person. The hospice social worker who facilitates, protects, and honors these community connections is providing the peer support that no clinical team member can replicate.
"The DMD patient has often done more research on his own disease than the adult clinicians he encounters after transition. He has read the Birnkrant consensus papers. He has read the trial data on eteplirsen. He knows what his FVC trajectory means. The social worker who asks 'what resources have been most helpful to you?' and then genuinely listens — rather than immediately referring to standard disease education materials the patient has long since outpaced — opens the right door."
Spirituality in a 26-year-old man with DMD is not the same as spirituality in a 75-year-old woman with cancer — but the need for meaning, legacy, connection, and peace is equally present and equally important. Use the FICA framework (Faith/beliefs, Importance, Community, Address) adapted specifically for a young adult with a lifelong diagnosis. Ask: "You've lived with this disease your entire life — what has given you strength through it?" This opens the most specific spiritual question in DMD and does not assume any religious tradition.[52]
The caregiver parent — the mother who has been caring since age five: She has twenty years of caregiving investment in this child. Her grief at the end of his life is the grief of a mother who watched every loss arrive, fought for every intervention, and now faces the final loss. She may struggle to hear her adult child's own end-of-life preferences — especially around limiting interventions — because she has spent twenty years doing the opposite.[53]
The advance directive conversation in DMD is unlike any other in hospice practice. The patient is cognitively intact, young, has thought about these decisions for years, and may already have strong, specific preferences about NIV withdrawal, tracheostomy, CPR, and other interventions that simply need to be documented. Do not assume the conversation is hard — for many DMD patients, it is a relief to finally have a clinical team asking the questions they have been thinking about alone for years.[47] The conversation that is truly hard is the one with the family — the parent who has not yet accepted that her child has preferences that may differ from her own wishes for him. The advance directive must be completed at enrollment, before any clinical event — NIV failure, respiratory infection, arrhythmia — makes the decision by default.
Passive wish for death ("I am tired of watching this happen to me") is common in advanced DMD and is often existentially appropriate in the context of a lifelong progressive illness — it is not the same as active suicidal ideation. Assessment requires careful, non-judgmental distinction: passive wish for death (common, often appropriate in advanced DMD — receive it without alarm and with presence), active suicidal ideation with plan (requires immediate psychiatric engagement), and medical aid in dying requests (legal in some jurisdictions — requires specific protocol and conversation that honors the patient's autonomy as a cognitively intact adult). The young adult with DMD who asks about hastened death deserves a full, respectful, non-dismissive clinical response — not a reflexive redirect. Document all conversations. Do not avoid the question.[47]
Plain language for families caring for a person with Duchenne muscular dystrophy at end of life. Share, print, or read aloud at the bedside.
You have been caring for this person for a long time — in many cases, since he was a small child who was first told what his disease was. You have fought alongside him through every loss, every hospitalization, every equipment change, every transition. What you are doing now is not different from what you have always done. It is the same love, the same presence, the same refusal to leave — and it is the most important thing anyone can offer. This guide is here to help you understand the medical equipment and medications so that you can manage the day-to-day with confidence, know when to call us, and focus your energy on being present rather than uncertain.
Breathing: Sudden severe breathing distress that the breathing machine is not relieving; mask coming off and your person unable to tolerate it back; breathing rate that seems very fast and your person looks frightened. The heart medications: Any clinician tells you to stop the lisinopril, perindopril, carvedilol, or metoprolol — call us first. Secretions: Your person cannot clear secretions even with full CoughAssist treatment; the color changes to dark green or your person has a fever. Consciousness: Your person is harder than usual to wake up, confused, or unresponsive. Skin: A reddened area on the hip, sacrum, or back that is not fading after repositioning. CoughAssist equipment: Any malfunction of the breathing machine or CoughAssist. Steroid emergency: Your person vomits and cannot keep the steroid down for two doses — call immediately; injectable steroid may be needed. Comfort concerns: Your person appears distressed, in pain, or frightened and you are not sure what to do — call us. That is exactly what we are here for.
🙏 You have been doing this for a long time. The weight of caring for someone with Duchenne muscular dystrophy across years and decades is one of the heaviest caregiving burdens in medicine — and you have carried it with love. The research on DMD caregiving shows that the families who provide this level of consistent, knowledgeable care make a measurable difference in their person's quality of life and comfort. You are not a bystander to his medical care. You are part of the clinical team — the most important part. Call us whenever you need us. We are here for you too, not just for him.
Clinical field wisdom from 12+ years at the bedside. What you learn after you've done enough of these. Not guidelines — real.
Peer-reviewed citations organized by clinical category. PMIDs hyperlinked to PubMed. Evidence levels assigned by article type.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. © Terminal2 | terminal2.care
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.